ArticleCancer2021
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.Blood advances · 2021Trial
- Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.Blood advances · 2026Article
- Racial disparities in multiple myeloma: biological heterogeneity, treatment access, and prognostic implications.Leukemia & lymphoma · 2026Review
- Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.Cancer medicine · 2025Article
- Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000-2020.British journal of haematology · 2025Article
- Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients.Cancer causes & control : CCC · 2025Article
- Racial differences in treatment and survival among older patients with multiple myeloma.Cancer medicine · 2024Article
- Addressing the disparities: the approach to the African American patient with multiple myeloma.Blood cancer journal · 2023Review
- Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study.Blood cancer journal · 2022Article
- Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.Frontiers in oncology · 2022Review
- Multiple myeloma with t(11;14): unique biology and evolving landscape.American journal of cancer research · 2022Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
36 authors at 20 institutions in 4 countries.
Funding
Abstract
backgroundMultiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard-risk MM, and it has been suggested to portend a worse prognosis in African Americans in comparison with Whites. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM of African American and White descent.
methodsThis study evaluated 3538 patients who underwent autologous hematopoietic cell transplantation (autoHCT) for MM from 2008 to 2016 and were reported to the CIBMTR. Patients were analyzed in 4 groups: African Americans with t(11;14) (n = 117), African Americans without t(11;14) (n = 968), Whites with t(11;14) (n = 266), and Whites without t(11;14) (n = 2187).
resultsAfrican Americans with t(11;14) were younger, had lower Karnofsky scores, and had more advanced stage MM with a higher Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI). Fewer African Americans with t(11;14) (21%) had a coexistent high-risk marker in comparison with Whites with t(11;14) (27%). In a multivariate analysis, race and t(11;14) had no association with progression-free survival. However, overall survival was superior among African Americans with t(11;14) in comparison with Whites with t(11;14) (hazard ratio, 0.53; 95% confidence interval, 0.30-0.93; P = .03). Survival was also associated with female sex, stage, time from diagnosis to transplant, a low HCT-CI, and receipt of maintenance.
conclusionsRace may have a differential impact on the survival of patients with t(11;14) MM who undergo autoHCT and needs to be further studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.